Nirma Limited has acquired a majority stake of 75% in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited for ₹5,651 crore at an enterprise value of ~₹7,500 crore. The acquisition will trigger an open offer.
Khaitan & Co advised Nirma Limited in this acquisition deal.
The core deal comprised Aashutosh Sampat (Partner), Mehul Shah (Partner), Rohan Shrivastava (Principal Associate), Sagarika Chandel (Senior Associate), Pranita Parakh (Associate) and Shalibhadra Daga (Associate).
Assistance on Securities law aspects - Arindam Ghosh (Partner), Shashank Patil (Principal Associate), Gaurang Mansinghka (Associate) and Shubhra Wadhawan (Associate).
Competition Law Aspects - Anisha Chand (Partner), Anshuman Sakle (Partner), Tanveer Verma (Principal Associate) and Rishabh Vora (Associate).
Intellectual Property aspect - Shailendra Bhandare (Partner), Sourav Dan (Principal Associate), Dr. Abdullah Khan (Senior Associate) and Kinjal Parikh (Associate).
Real Estate aspects - Abhiraj Gandhi (Partner) and Nirali Shah (Senior Associate).
Employment Law aspects - Deepak Kumar (Partner), Deeksha Mallik (Senior Associate) and Ransher Singh (Associate).
Trilegal represented Glenmark Life Sciences in this deal.
The transaction team was led by Yogesh Singh (Partner and National Head of Corporate Practice) along with Tejas Adiga (Corporate Partner) and Atul Gupta (Labour and Employment Partner).
Other attorneys who supported the deal include Kosha Thaker (Counsel), Arunima Singal and Rohan Kohli (Senior Associates), Daksha Khanna, Abhijit Bhandarkar, Adit Munshi and Nikita Rajesh (Associates) on corporate aspects; and Parvathy Tharamel (Counsel) on employment law matters.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.